Product information
From Health Canada
The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.
Current status:
Approved
Current status date:
2020-10-30
Product name:
IDACIO
Description:
SINGLE USE VIAL
DIN:
02502666
Product Monograph/Veterinary Labelling:
Date:
2024-07-23
Product monograph/Veterinary Labelling (PDF version ~ 175K)
Company:
FRESENIUS KABI CANADA LTD
165 Galaxy Blvd, Suite 100
Toronto
Ontario
Canada
M9W 0C8
Class:
Human
Dosage form(s):
Solution
Route(s) of administration:
Subcutaneous
Number of active ingredient(s):
1
Schedule(s):
Prescription , Schedule D
Biosimilar Biologic Drug:
Yes
American Hospital Formulary Service (AHFS): See footnote 3
92:36.00
Anatomical Therapeutic Chemical (ATC): See footnote 4
L04AB04 ADALIMUMAB
Active ingredient group (AIG) number:See footnote5
0150364003
| Active ingredient(s) See footnote8 | Strength |
|---|---|
| ADALIMUMAB | 40 MG / 0.8 ML |
Risk Management Plans See footnote 7
A Risk Management Plan (RMP) for this product was submitted.
| Additional Risk Minimization Measures |
|---|
| Patient Wallet Card |
| Pharmacovigilance/Monitoring Activity |
|---|
| Observational Studies |